TOP TEN perturbations for 1169_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1169_at
Selected probe(set): 1552662_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1169_at (1552662_a_at) across 6673 perturbations tested by GENEVESTIGATOR:
glioma study 16 (LN-319) / normal astrocyte sample
Relative Expression (log2-ratio):1.7923326Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-319) |
| Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
sarcoidosis study 6 (orbital adipose tissue) / normal orbital adipose tissue
Relative Expression (log2-ratio):-1.7187691Number of Samples:7 / 22
| Experimental | sarcoidosis study 6 (orbital adipose tissue) |
| Orbital adipose tissue samples obtained from patients who suffered from sarcoidosis. Biopsies were formalin-fixed and paraffin-embedded. | |
| Control | normal orbital adipose tissue |
| Normal orbital adipose tissue samples. Samples were obtained from subjects with no history of orbital disease at the time of surgery such as fat typically excised and discarded as part of routine blepharoplasty or retrobulbar fat that is snared with the eye during enucleation. Biopsies were formalin-fixed and paraffin-embedded. |
glioma study 27 (glioblastoma, NOS) / glioma study 27 (astrocytoma, NOS)
Relative Expression (log2-ratio):-1.555624Number of Samples:4 / 5
| Experimental | glioma study 27 (glioblastoma, NOS) |
| Primary tumor samples from resected brain tissues of patients with glioblastoma, NOS(WHO grade IV astrocytoma). | |
| Control | glioma study 27 (astrocytoma, NOS) |
| Primary tumor samples from resected brain tissues of patients with astrocytoma, NOS (WHO grade II astrocytoma). |
thyroid eye disease study 1 (orbital adipose tissue) / sarcoidosis study 6 (orbital adipose tissue)
Relative Expression (log2-ratio):1.4516106Number of Samples:27 / 7
| Experimental | thyroid eye disease study 1 (orbital adipose tissue) |
| Orbital adipose tissue samples obtained from patients who suffered from thyroid eye disease (TED). Biopsies were formalin-fixed and paraffin-embedded. | |
| Control | sarcoidosis study 6 (orbital adipose tissue) |
| Orbital adipose tissue samples obtained from patients who suffered from sarcoidosis. Biopsies were formalin-fixed and paraffin-embedded. |
granulomatosis with polyangiitis study 3 (orbital adipose tissue) / normal orbital adipose tissue
Relative Expression (log2-ratio):-1.3452864Number of Samples:9 / 22
| Experimental | granulomatosis with polyangiitis study 3 (orbital adipose tissue) |
| Orbital adipose tissue samples obtained from patients who suffered from granulomatosis with polyangiitis (GPA). Biopsies were formalin-fixed and paraffin-embedded. | |
| Control | normal orbital adipose tissue |
| Normal orbital adipose tissue samples. Samples were obtained from subjects with no history of orbital disease at the time of surgery such as fat typically excised and discarded as part of routine blepharoplasty or retrobulbar fat that is snared with the eye during enucleation. Biopsies were formalin-fixed and paraffin-embedded. |
atypical teratoid/rhabdoid tumor study 1 / non-tumor brain tissue
Relative Expression (log2-ratio):1.3191109Number of Samples:20 / 9
| Experimental | atypical teratoid/rhabdoid tumor study 1 |
| Primary tumor tissue sample from the brain of pediatric patients with atypical teratoid/rhabdoid tumor (AT/RT). | |
| Control | non-tumor brain tissue |
| Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor. |
glioma study 16 (BS-149) / normal astrocyte sample
Relative Expression (log2-ratio):1.2706003Number of Samples:2 / 3
| Experimental | glioma study 16 (BS-149) |
| Human glioma cell line BS149 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
cutaneous T-cell lymphoma study 1 (tumor phase) / normal skin tissue
Relative Expression (log2-ratio):-1.2674475Number of Samples:4 / 8
| Experimental | cutaneous T-cell lymphoma study 1 (tumor phase) |
| Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal). | |
| Control | normal skin tissue |
| Skin biopsies from healthy individuals. |
atypical teratoid/rhabdoid tumor study 1 / primitive neuroectodermal tumor study 1
Relative Expression (log2-ratio):1.2198105Number of Samples:20 / 9
| Experimental | atypical teratoid/rhabdoid tumor study 1 |
| Primary tumor tissue sample from the brain of pediatric patients with atypical teratoid/rhabdoid tumor (AT/RT). | |
| Control | primitive neuroectodermal tumor study 1 |
| Primary tumor tissue sample from the supratentorial brain of pediatric patients with primitive neuroectodermal tumor. |
angiopoietin-1 study 1 (sparse) / angiopoietin-1 study 1 (confl.)
Relative Expression (log2-ratio):-1.167984Number of Samples:2 / 2
| Experimental | angiopoietin-1 study 1 (sparse) |
| Sparse human umbilical vein endothelial cells stimulated with 100 ng /ml COMP-Angiopoietin-1 for 1h after starvation overnight. | |
| Control | angiopoietin-1 study 1 (confl.) |
| Confluent human umbilical vein endothelial cells stimulated with 100 ng /ml COMP-Angiopoietin-1 for 1h after starvation overnight. |
Organism: Homo sapiens
Gene: 1169_at
Selected probe(set): 211875_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1169_at (211875_x_at) across 6673 perturbations tested by GENEVESTIGATOR:
atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):-1.6033735Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (non-lesional; whole skin) |
| Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
colorectal cancer study 33 (carcinoma; colonic crypt) / normal colonic crypt epithelial cell sample
Relative Expression (log2-ratio):1.4646988Number of Samples:5 / 5
| Experimental | colorectal cancer study 33 (carcinoma; colonic crypt) |
| Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma. | |
| Control | normal colonic crypt epithelial cell sample |
| Histopathological normal colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer. |
atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):-1.3366203Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (lesional; whole skin) |
| Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
expO ovary cancer study 1 (serous cystadenoma; borderline malignancy) / expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic)
Relative Expression (log2-ratio):-1.2683792Number of Samples:2 / 8
| Experimental | expO ovary cancer study 1 (serous cystadenoma; borderline malignancy) |
| Tumor tissue samples obtained from the ovary of patients with serous cystadenoma. | |
| Control | expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary. |
colorectal cancer study 33 (carcinoma; colonic crypt) / adjacent colonic crypt epithelial cell sample
Relative Expression (log2-ratio):1.2186527Number of Samples:5 / 5
| Experimental | colorectal cancer study 33 (carcinoma; colonic crypt) |
| Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma. | |
| Control | adjacent colonic crypt epithelial cell sample |
| Adjacent colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from patients with colorectal cancer. |
expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic)
Relative Expression (log2-ratio):1.2034054Number of Samples:8 / 2
| Experimental | expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary. | |
| Control | expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary mucinous adenocarcinoma of the ovary. |
expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Relative Expression (log2-ratio):-1.1807976Number of Samples:2 / 2
| Experimental | expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary mucinous adenocarcinoma of the ovary. | |
| Control | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. |
colorectal cancer study 33 (carcinoma; colonic mucosa) / normal colon mucosa sample
Relative Expression (log2-ratio):1.1795568Number of Samples:5 / 5
| Experimental | colorectal cancer study 33 (carcinoma; colonic mucosa) |
| Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma. | |
| Control | normal colon mucosa sample |
| Histopathological normal colon mucosa sample obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer. |
expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary) / expO ovary cancer study 1 (endometrioid and papillary serous adenocarcinoma; primary)
Relative Expression (log2-ratio):1.0893106Number of Samples:3 / 4
| Experimental | expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with malignant mixed Mullerian tumor. | |
| Control | expO ovary cancer study 1 (endometrioid and papillary serous adenocarcinoma; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with endometrioid and papillary serous adenocarcinoma. |
expO ovary cancer study 1 (endometrioid and papillary serous adenocarcinoma; primary) / expO ovary cancer study 1 (carcinoma, NOS; primary)
Relative Expression (log2-ratio):-1.0752392Number of Samples:4 / 2
| Experimental | expO ovary cancer study 1 (endometrioid and papillary serous adenocarcinoma; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with endometrioid and papillary serous adenocarcinoma. | |
| Control | expO ovary cancer study 1 (carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with carcinoma (NOS). |